Just eight seconds into the start of the 2025 award show season, Nikki Glaser, the host of the 82nd Golden Globes, dubbed the show “Ozempic’s biggest night.” The comedian wasn’t joking. She’s following the lead of Jimmy Kimmel,

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks. Mimicking three hormones, it outperforms FDA-approved treatments like Ozempic and Wegovy.

"Ozempic Santa" Elon Musk revealed he's been using a type 2 diabetes medication to lose weight: "Technically, Mounjaro, but that doesn’t have the same ring to it."

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, whether they utilize weight loss drugs or not,” IBX said in a statement.

Elon Musk has many speculating that he has used Ozempic to lose weight. The owner of X posted on the platform on Wednesday (Dec. 25). In his post, he shared a picture of him wearing a Santa outfit where he looked slimmer. However, it was his caption that sparked speculation that he was on the weight loss drug Ozempic.

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on Medicaid and have become yo-yo dieters who, despite their best efforts at changing their eating habits and lifestyles,

Ozempic 3.0? Retatrutide — an experimental drug nicknamed “triple G” — could be your best shot at a slimmer waistline when it becomes available to the public, a Monday study found. Obese adults who took the weekly injection lost up to 22% of their starting weight after 11 months — compared to just 14% over 15 months for semaglutide,

McGill University researchers say their study has found GLP-1 drugs are safe and effective for treating obesity and overweight adults without diabetes. The authors say the findings support using the medication to treat those who are overweight and obese among otherwise healthy patients.

The U.S. FDA has released a new draft guidance for drugmakers to aid them in developing new treatments for obesity. The new document replaces an earlier draft guidance issued in February 2007. The new guidance stated that its focus is on the design of clinical trials and endpoints to demonstrate sustained weight loss,